CD38 and neoplasm: Here we show that JK36 also detects CD38-expressing tumor cells with greater sensitivity than monoclonal antibody HIT2PerCP/Cy5.5 which is currently being used in flow cytometric assays (45–47) to assess treatment response in patients receiving daratumumab.